ANVS
Annovis Bio, Inc.stockNYSE
annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.84 | 2026-11-06 | +9.13% | 2.510 |
| 1M | 1.06 | 2026-10-13 | -13.02% | 5.959 |
| 3M | 1.79 | 2026-08-13 | -48.49% | 4.503 |
| 6M | 2.22 | 2026-05-13 | -58.47% | 3.111 |
| 1Y | 2.29 | 2025-11-13 | -59.74% | 2.384 |
| 2Y | 7.41 | 2024-11-13 | -87.56% | — |
| 5Y | 30.01 | 2021-11-12 | -96.93% | 1.602 |
Annovis Bio, Inc. (NYSE:ANVS) stock price today is $0.92, and today's volume is 2,197,306. ANVS is up 8.829% today. The 30 day average volume is 2.41M. ANVS market cap is $39.67M with 43.02M shares outstanding.